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INTRODUCTION
Propofol infusion syndrome (PRIS)  
is a rare and fatal syndrome that can 
be caused by doses of propofol that 
 exceed 4mg/kg/hr for more than  
48 hours. Concurrent use of cate­
cholamines and glucocorticoids  
while  using propofol has also been 
linked  with PRIS.1 PRIS can present 
with  different symptoms including 
 arrhythmias, metabolic/lactic acidosis, 
rhabdomyolysis, renal failure, hypertri­
glyceridemia, and cardiac failure. 
Symptoms can be  associated with 
variables such as the rate of infusion 
(cardiac failure and metabolic acidosis), 
the duration of the infusion (arrhythmias), 
or to the  cumulative amount of propofol 
used (rhabdomyolysis and hypertri­
glyceridemia).2 These associations 
help  predict symptoms but are not 
strict rules. 
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CASE DESCRIPTION
55­year­old female with past medical history of type  
1 diabetes presented on day 3 as a transfer from an 
outside hospital with worsening hypoxia and day 3 of 
ventilator support due to parainfluenza pneumonia. 
Physical exam was limited due to sedation with 
remarkable findings including bilateral breath sounds 
present with end expiratory crackles more prominent  
on the right lung base. Abdominal distention was noted 
with 1+ pitting edema in the upper and lower extremities. 
The dose of propofol on admission was 50 mcg/kg/min 
and was slowly increased to a max dose of 80 mcg/kg/
min over the next 3 days. Lab abnormalities on day  
6 of hospitalization included creatinine 2.18 mg/dL, 
potassium 5.9 mmol/L, bicarbonate 13 mmol/L, 
triglyceride 2,192 mg/dL, and creatinine kinase total (CK) 
1,483 U/L Based on the lab results, the patient had 
developed acute renal failure, severe metabolic acidosis, 
hyperkalemia, severe hypertriglyceridemia, and 
rhabdomyolysis which increased the suspicion for PRIS. 
The patient was promptly started on continuous renal 
replacement therapy (CRRT) for the acute renal failure 
and started on an insulin drip for the hypertriglyceridemia 
which resolved within 24 hours. Her CK normalized 
within 3 days. Thankfully the patient was subsequently 
taken off the CRRT and recovered fully prior to leaving 
the hospital. 
DISCUSSION
Due to its favorable pharmacological properties, 
propofol is one of the more commonly used 
agents for sedation in the ICU setting.3 PRIS is a 
rare but potentially fatal syndrome with mortality 
rates reaching as high as 66%. Due to its high 
mortality rates it is important for physicians to 
monitor for early signs of PRIS in order to 
decrease the risk of poor outcomes. The current 
mainstay of treatment is switching to a different 
sedative and providing supportive care to the 
patient. In the case presented above the cessation 
of propofol and management of its symptoms  
and complications led to the patient’s eventual 
recovery from PRIS; however, it did increase the 
length of stay by a considerable amount.
